TNF-Bound Colloidal Gold in Treating Patients With Advanced Solid Tumors

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed solid tumor
• Advanced and/or metastatic disease
• Unresponsive to conventional therapy (i.e., disease progressed while receiving any known standard curative or palliative therapy) OR previously untreated tumor for which no standard treatment exists
• Measurable or evaluable metastatic disease
• No lymphoma or other hematologic malignancy
• No known brain metastases
• * Previously treated brain metastases with no evidence of recurrence allowed
• PATIENT CHARACTERISTICS:
• ECOG performance status 0-2
• Life expectancy ≥ 3 months
• Absolute neutrophil count ≥ 1,500/mm³
• Platelet count ≥ 100,000/mm³
• Creatinine ≤ 2.0 mg/dL
• Bilirubin ≤ 2.5 mg/dL
• ALT and AST ≤ 1.5 times upper limit of normal (ULN) (3 times ULN if liver metastases are present)
• Alkaline phosphatase ≤ 1.5 times ULN (3 times ULN if liver metastases are present)
• Prothrombin time ≤ 1.5 times ULN
• Hemoglobin ≥ 10.0 g/dL (transfusion allowed)
• LVEF ≥ 45% by echocardiogram or thallium stress test for patients \> 50 years of age or history of cardiovascular disease
• FEV\_1 and DLCO \> 30% of predicted for patients with a history of pulmonary disease
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No active bacterial or viral infection with systemic manifestations (e.g., fever, symptoms, leukocytosis)
• * Localized chronic infections, such as mild acne or tinea pedis allowed
• No acute or chronic viral hepatitis
• No known bleeding disorder
• No other concurrent life-threatening illness, including any of the following:
• * Unstable angina
• * Severe oxygen-dependent chronic obstructive pulmonary disease
• * End-stage liver disease
• No known active renal disease or renal insufficiency as evidenced by serum creatinine \> 2.0 mg/dL
• No HIV positivity
• PRIOR CONCURRENT THERAPY:
• Recovered from prior therapy
• More than 3 weeks since prior biological or cytotoxic agents (6 weeks for nitrosoureas)
• No known requirment for palliative treatment
• No concurrent surgery
• No other concurrent anticancer therapy